These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 31277703)

  • 21. Effect of Class II HDAC inhibition on glutamate transporter expression and survival in SOD1-ALS mice.
    Lapucci A; Cavone L; Buonvicino D; Felici R; Gerace E; Zwergel C; Valente S; Mai A; Chiarugi A
    Neurosci Lett; 2017 Aug; 656():120-125. PubMed ID: 28732762
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Class I and II histone deacetylase expression is not altered in human amyotrophic lateral sclerosis: Neuropathological and positron emission tomography molecular neuroimaging evidence.
    Dios AM; Babu S; Granucci EJ; Mueller KA; Mills AN; Alshikho MJ; Zürcher NR; Cernasov P; Gilbert TM; Glass JD; Berry JD; Atassi N; Hooker JM; Sadri-Vakili G
    Muscle Nerve; 2019 Oct; 60(4):443-452. PubMed ID: 31241177
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Epigenetic Changes Associated with the Expression of Amyotrophic Lateral Sclerosis (ALS) Causing Genes.
    Masala A; Sanna S; Esposito S; Rassu M; Galioto M; Zinellu A; Carru C; Carrì MT; Iaccarino C; Crosio C
    Neuroscience; 2018 Oct; 390():1-11. PubMed ID: 30134203
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Additive neuroprotective effects of a histone deacetylase inhibitor and a catalytic antioxidant in a transgenic mouse model of amyotrophic lateral sclerosis.
    Petri S; Kiaei M; Kipiani K; Chen J; Calingasan NY; Crow JP; Beal MF
    Neurobiol Dis; 2006 Apr; 22(1):40-9. PubMed ID: 16289867
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [A mice model of amyotrophic lateral sclerosis expressing mutant human FUS protein].
    Deĭkin AV; Kovrazhkina EA; Ovchinnikov RK; Bronovitskiĭ EV; Razinskaia OD; Smirnov AP; Ermolkevich TG; Eliakov AB; Popov AN; Fedorov EN; Lytkina OA; Kukharskiĭ MS; Tarasova TV; Shelkovnikova TA; Ustiugov AA; Ninkina NN; Gol'dman IL; Sadchikova ER; Bachurin SO; Skvortsova VI
    Zh Nevrol Psikhiatr Im S S Korsakova; 2014; 114(8):62-9. PubMed ID: 25345633
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Epigenetic Mechanisms of Gene Regulation in Amyotrophic Lateral Sclerosis.
    Jimenez-Pacheco A; Franco JM; Lopez S; Gomez-Zumaquero JM; Magdalena Leal-Lasarte M; Caballero-Hernandez DE; Cejudo-Guillén M; Pozo D
    Adv Exp Med Biol; 2017; 978():255-275. PubMed ID: 28523551
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combination of a Histone Deacetylase 6 Inhibitor and a Somatostatin Receptor Agonist Synergistically Reduces Hepatorenal Cystogenesis in an Animal Model of Polycystic Liver Disease.
    Lorenzo Pisarello M; Masyuk TV; Gradilone SA; Masyuk AI; Ding JF; Lee PY; LaRusso NF
    Am J Pathol; 2018 Apr; 188(4):981-994. PubMed ID: 29366679
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibition of monomethylarsonous acid (MMA(III))-induced cell malignant transformation through restoring dysregulated histone acetylation.
    Ge Y; Gong Z; Olson JR; Xu P; Buck MJ; Ren X
    Toxicology; 2013 Oct; 312():30-5. PubMed ID: 23891734
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Histone Deacetylase Inhibitors and Diabetic Kidney Disease.
    Hadden MJ; Advani A
    Int J Mol Sci; 2018 Sep; 19(9):. PubMed ID: 30189630
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Multiple roles of HDAC inhibition in neurodegenerative conditions.
    Chuang DM; Leng Y; Marinova Z; Kim HJ; Chiu CT
    Trends Neurosci; 2009 Nov; 32(11):591-601. PubMed ID: 19775759
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Selectivity and Kinetic Requirements of HDAC Inhibitors as Progranulin Enhancers for Treating Frontotemporal Dementia.
    She A; Kurtser I; Reis SA; Hennig K; Lai J; Lang A; Zhao WN; Mazitschek R; Dickerson BC; Herz J; Haggarty SJ
    Cell Chem Biol; 2017 Jul; 24(7):892-906.e5. PubMed ID: 28712747
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative interactomics analysis of different ALS-associated proteins identifies converging molecular pathways.
    Blokhuis AM; Koppers M; Groen EJN; van den Heuvel DMA; Dini Modigliani S; Anink JJ; Fumoto K; van Diggelen F; Snelting A; Sodaar P; Verheijen BM; Demmers JAA; Veldink JH; Aronica E; Bozzoni I; den Hertog J; van den Berg LH; Pasterkamp RJ
    Acta Neuropathol; 2016 Aug; 132(2):175-196. PubMed ID: 27164932
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inhibition of histone deacetylases.
    Liu C; Xu D
    Methods Mol Biol; 2004; 287():87-97. PubMed ID: 15273406
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibition of histone deacetylases by Trichostatin A leads to a HoxB4-independent increase of hematopoietic progenitor/stem cell frequencies as a result of selective survival.
    Obier N; Uhlemann CF; Müller AM
    Cytotherapy; 2010 Nov; 12(7):899-908. PubMed ID: 20210674
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Histone deacetylation and motor neuron degeneration.
    Schmalbach S; Petri S
    CNS Neurol Disord Drug Targets; 2010 Jul; 9(3):279-84. PubMed ID: 20406183
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Genome-wide histone acetylation is altered in a transgenic mouse model of Huntington's disease.
    McFarland KN; Das S; Sun TT; Leyfer D; Xia E; Sangrey GR; Kuhn A; Luthi-Carter R; Clark TW; Sadri-Vakili G; Cha JH
    PLoS One; 2012; 7(7):e41423. PubMed ID: 22848491
    [TBL] [Abstract][Full Text] [Related]  

  • 37. HDAC inhibition attenuates cardiac hypertrophy by acetylation and deacetylation of target genes.
    Ooi JY; Tuano NK; Rafehi H; Gao XM; Ziemann M; Du XJ; El-Osta A
    Epigenetics; 2015; 10(5):418-30. PubMed ID: 25941940
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Histone acetylation as a potential therapeutic target in motor neuron degenerative diseases.
    Garbes L; Riessland M; Wirth B
    Curr Pharm Des; 2013; 19(28):5093-104. PubMed ID: 23448465
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Potential Therapeutic Role of HDAC Inhibitors in FUS-ALS.
    Tejido C; Pakravan D; Bosch LVD
    Front Mol Neurosci; 2021; 14():686995. PubMed ID: 34434087
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease.
    Hockly E; Richon VM; Woodman B; Smith DL; Zhou X; Rosa E; Sathasivam K; Ghazi-Noori S; Mahal A; Lowden PA; Steffan JS; Marsh JL; Thompson LM; Lewis CM; Marks PA; Bates GP
    Proc Natl Acad Sci U S A; 2003 Feb; 100(4):2041-6. PubMed ID: 12576549
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.